A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data And Analyst Coverage

Neurocrine Biosciences (NBIX) is back in focus after new real world survey data on INGREZZA in mild tardive dyskinesia, along with fresh analyst coverage, increased attention on how this franchise and pipeline might support the stock.

See our latest analysis for Neurocrine Biosciences.

The recent real world INGREZZA data and fresh analyst coverage arrive as momentum in Neurocrine Biosciences’ stock has been picking up, with a 21.70% 1 month share price return and a 26.66% 1 year total shareholder return, pointing to growing investor interest in the long term story.

If this kind of pipeline news has you thinking bigger, it could be a good moment to use our screener to look across 33 healthcare AI stocks

With Neurocrine delivering double digit annual revenue and net income growth and the stock trading at a discount to both published analyst targets and some intrinsic value estimates, the key question is whether there is still an opportunity for investors here or if the market is already pricing in future growth.

Most Popular Narrative: 16.4% Undervalued

With Neurocrine Biosciences last closing at $155.83 against a narrative fair value of $186.45, the current price sits below what this narrative framework suggests.

Rapid and consistent early adoption of CRENESSITY, with high rates of reimbursement and a strong clinical profile in a condition with significant unmet need, is a key element of the long term revenue story. If that uptake continues to build from this base, it has the potential to meaningfully expand the top line while improving operating leverage over time.

Read the complete narrative.

Want to see what sits behind that confidence in future cash generation and earnings power? The narrative leans heavily on compounding revenue, rising margins, and a richer profit mix.

Result: Fair Value of $186.45 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, you also need to keep an eye on potential pricing pressure around INGREZZA contracts and the concentration risk if INGREZZA and CRENESSITY underperform expectations.

Find out about the key risks to this Neurocrine Biosciences narrative.

Next Steps

If this mix of optimism and caution resonates, act while the data is fresh and pressure test the thesis yourself by reviewing the 4 key rewards

Looking for more investment ideas?

If Neurocrine Biosciences has sharpened your thinking, do not stop here. Broaden your watchlist with other stocks that might fit your style and goals.

• Target reliable income streams by checking out 9 dividend fortresses that may offer stronger yield support for your portfolio.
• Hunt for quality at a potential discount with screener containing 22 high quality undiscovered gems that many investors might not be watching yet.
• Dial back portfolio stress by reviewing 64 resilient stocks with low risk scores that score well on resilience and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com